Companies: 10,795·Total market cap: $144.5T
NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc.

NRXPNASDAQHealthcare● Active
$4.34
+$0.01(+0.23%)
Market Cap$75019999
P/E Ratio
52W High$5.055
52W Low$1.62
Overview

NRx Pharmaceuticals, Inc. (NRXP) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001719406 · NRXP · NASDAQ · as of Jun 9, 2026

Filing snapshot

464
Total Filings
8-K
Latest Form
2026-06-04
Most Recent
2017
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001719406 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-23
Fiscal Year End
Mar 23, 2026
Accession No.
0001437749-26-009418
Primary Document
nrxp20251231_10k.htm
Source: data.sec.gov · CIK 0001719406 · Accession 0001437749-26-009418

Latest Key Filings

10-QQuarterly Report
FORM 10-Q
2026-05-15
8-KCurrent Report
FORM 8-K
2026-06-04Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
FORM 8-K
2026-06-04
View
424B5424B5
FORM 424B5
2026-06-03
View
8-KCurrent Report
FORM 8-K
2026-06-02
View
424B5424B5
FORM 424B5
2026-06-02
View
25-NSE25-NSE
25-NSE
2026-05-22
View
10-QQuarterly Report
FORM 10-Q
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
8-KCurrent Report
FORM 8-K
2026-03-24
View
10-KAnnual Report
FORM 10-K
2026-03-23
View
DEFA14AProxy Statement (Additional)
FORM DEFA14A
2026-02-24
View
ARSARS
ARS
2026-02-23
View
DEF 14AProxy Statement
FORM DEF 14A
2026-02-23
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-02-17
View
8-KCurrent Report
FORM 8-K
2026-02-17
View
8-KCurrent Report
FORM 8-K
2026-02-17
View
Showing 1–15 of 413 filingsForm 4 / 144 hidden· 464 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001719406  |  Exchange: NASDAQ · Healthcare

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) has submitted 464 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2017. As a Healthcare sector company with CIK 0001719406, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is NRx Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent NRx Pharmaceuticals, Inc. 10-K was filed on 2026-03-23 for fiscal year ending 2026. Historical NRXP 10-K annual reports are available from 2017 through 2026.

Investors researching NRx Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

NRXP SEC Filings · 8 questions

NRx Pharmaceuticals, Inc. (NRXP) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 464 filings and access original documents at no cost. NRx Pharmaceuticals, Inc.'s CIK is 0001719406.

NRXP SEC filingsNRx Pharmaceuticals, Inc. SEC documentsfind NRXP 10-K